Nexavar Approved for Liver Cancer in China

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced that the State Food and Drug Administration (SFDA) of China has approved Nexavar (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma, or liver cancer.
Fox Business